Figure 2: From symptom-based to a systems approach for classification of FGIDs.

FGIDs are currently classified based on symptoms, which provides a framework for clinical studies but as we move towards more comprehensive profiling of patients using multi-omics and physiologic changes in addition to symptoms, we can envision a future state which will allow for stratification of patients by integrating multiple data layers collected longitudinally. Such a stratification strategy will not only allow for development of mechanism-based targeted therapeutics but will also allow identification of appropriate patient cohorts which are most likely to benefit from such a therapy.